Outpatient antibiotic use in Dutch infants after 10-valent pneumococcal vaccine introduction: a time-series analysis

被引:7
|
作者
Fortanier, Alexandre C. [1 ]
Venekamp, Roderick P. [1 ]
Stellato, Rebecca K. [1 ]
Sanders, Elisabeth A. M. [2 ,3 ]
Damoiseaux, Roger A. M. J. [1 ]
Hoes, Arno W. [1 ]
Schilder, Anne M. [1 ,4 ]
机构
[1] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[2] Univ Utrecht, Univ Med Ctr, Dept Paediat Immunol & Infect Dis, Utrecht, Netherlands
[3] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[4] UCL, Ear Inst, evidENT, London, England
来源
BMJ OPEN | 2018年 / 8卷 / 06期
关键词
CONJUGATE VACCINE; OTITIS-MEDIA; IMPACT; CHILDREN; HOSPITALIZATION; PROGRAMS; TRENDS;
D O I
10.1136/bmjopen-2017-020619
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective This population-based cohort study assesses the impact of switching from a 7-valent pneumococcal conjugate vaccine (PCV) to a 10-valent PCV on outpatient antibiotic use in Dutch infants, and whether geographical vaccination coverage modifies this association. Setting and participants We extracted 2006-2013 anonymised antibiotic purchase data of 255 154 Dutch infants aged below 2 years from Achmea Health, a health insurance fund covering 28% of the national population. Design and main outcome measure Changes in monthly antibiotic use from 2006-2011 (PCV7) to 2011-2013 (PCV10) were estimated using time-series analysis accounting for seasonality and autocorrelation. Interaction terms for vaccination coverage (categorised into seven groups) and period were added to the model to test whether this association was vaccination coverage dependent. Results 275337 antibiotic courses were used by 119 078 infants (461 352 person-years). PCV10 introduction was associated with a modest 1.6% overall reduction in antibiotic use (purchase rate ratio: 0.98, 95% CI: 0.98 to 0.99). Our model showed a significant difference in time trend in antibiotic use after PCV10 introduction (p=0.0084) with an increase in prescriptions in the PCV7 period (slope: 0.0023/month, 95% CI: -0.0001 to 0.0047) versus a decline in the PCV10 period (slope: -0.0089/month, 95% CI: -0.0150 to -0.0029). There was no evidence that PCV vaccination coverage affected this association, but since the largest rate ratios were observed in municipalities with the lowest vaccine coverage and had very wide accompanying Cls, our study might have insufficient power to detect such an association. Conclusions Switching from PCV7 to PCV10 was associated with a modest decline in outpatient antibiotic use in Dutch infants.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
    Rozenbaum, Mark H.
    Sanders, Elisabeth A. M.
    van Hoek, Albert Jan
    Jansen, Angelique G. S. C.
    van der Ende, Arie
    van den Dobbelsteen, Germie
    Rodenburg, Gerwin D.
    Hak, Eelko
    Postma, Maarten J.
    BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : 1347
  • [22] Early Declines in Vaccine Type Pneumococcal Carriage in Children Less Than 5 Years Old After Introduction of 10-valent Pneumococcal Conjugate Vaccine in Mozambique
    Sigauque, Betuel
    Moiane, Benild
    Massora, Sergio
    Pimenta, Fabiana
    Verani, Jennifer R.
    Mucavele, Helio
    Chauque, Alberto
    Quinto, Llorenc
    dos Santos, Rita T.
    da Gloria Carvalho, Maria
    Whitney, Cynthia G.
    Lessa, Fernanda C.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (10) : 1054 - 1060
  • [23] Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
    Hanquet, Germaine
    Krizova, Pavla
    Dalby, Tina
    Ladhani, Shamez N.
    Nuorti, J. Pekka
    Danis, Kostas
    Mereckiene, Jolita
    Knol, Mirjam J.
    Winje, Brita A.
    Ciruela, Pilar
    de Miguel, Sara
    Eugenia Portillo, Maria
    MacDonald, Laura
    Morfeldt, Eva
    Kozakova, Jana
    Valentiner-Branth, Palle
    Fry, Norman K.
    Rinta-Kokko, Hanna
    Varon, Emmanuelle
    Corcoran, Mary
    van der Ende, Arie
    Vestrheim, Didrik F.
    Munoz-Almagro, Carmen
    Sanz, Juan-Carlos
    Castilla, Jesus
    Smith, Andrew
    Henriques-Normark, Birgitta
    Colzani, Edoardo
    Pastore-Celentano, Lucia
    Savulescu, Camelia
    EMERGING INFECTIOUS DISEASES, 2022, 28 (01) : 127 - 138
  • [25] Susceptibility profiles and correlation with pneumococcal serotypes soon after implementation of the 10-valent pneumococcal conjugate vaccine in Brazil
    Mott, Mariana
    Caierao, Juliana
    da Cunha, Gabriela Rosa
    Rodrigues Perez, Leandro Reus
    Matusiak, Roberto
    Pilger de Oliveira, Katia Ruschel
    d'Azevedo, Pedro Alves
    Dias, Cicero
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 20 : 47 - 51
  • [26] Improving Capture of Vaccine History: Case Study from an Evaluation of 10-Valent Pneumococcal Conjugate Vaccine Introduction in Kenya
    Harris, Aaron M.
    Aol, George
    Ouma, Dominic
    Bigogo, Godfrey
    Montgomery, Joel M.
    Whitney, Cynthia G.
    Breiman, Robert F.
    Kim, Lindsay
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2016, 94 (06): : 1400 - 1402
  • [27] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV) Versus 10-Valent PCVs in Filipino Infants
    Perdrizet, J.
    Horn, E.
    Nua, W.
    Perez Peralta, J.
    Nailes, J.
    Santos, J.
    Ong-Lim, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S118 - S118
  • [28] Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil
    Brandileone, Maria-Cristina C.
    Almeida, Samanta C. G.
    Minamisava, Ruth
    Andrade, Ana-Lucia
    VACCINE, 2018, 36 (19) : 2559 - 2566
  • [30] Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
    van Westen, Els
    Knol, Mirjam J.
    Wijmenga-Monsuur, Alienke J.
    Tcherniaeva, Irina
    Schouls, Leo M.
    Sanders, Elisabeth A. M.
    van Els, Cecile A. C. M.
    Berbers, Guy A. M.
    Rots, Nynke Y.
    VACCINES, 2018, 6 (04):